Novo Nordisk's Oral Ambition Meets a Pipeline Reality Check

Novo Nordisk's oral Wegovy gains market share in UK and US, but pipeline setbacks and Goldman's CagriSema cut raise questions about future growth.

The Danish pharma giant is telling two stories at once these days, and the market is struggling to decide which one matters more. On one hand, the company's flagship oral weight-loss pill is off to a blistering start in Britain and poised to land in Germany on September 1. On the other, the pipeline beyond semaglutide keeps throwing up disappointments that have forced at least one major bank to slash its peak sales estimates by more than half.

The Pill's Momentum

The oral version of Wegovy has already rewritten the rulebook in the UK. Novo Nordisk claims a 90 percent market share there, with 300,000 patients signed up within just three weeks of launch. That kind of velocity suggests the convenience factor is real — removing the injection needle appears to be lowering the psychological barrier that has kept many patients away from GLP-1 therapies.

The company is betting big on this shift. A €432 million investment in Irish production facilities is earmarked specifically for oral medications, an acknowledgment that supply constraints have haunted the injectable market for years. CFO Karsten Munk Knudsen made clear during the quarterly results presentation that the oral rollout now sits at the center of corporate strategy.

Stateside, the numbers are equally encouraging. The Wegovy pill has surpassed 5 million prescriptions since launch, with weekly scripts topping 265,000 in the week ending July 17. Novo Nordisk maintains that the Wegovy franchise remains the market leader among branded obesity drugs in the US.

A Raised Forecast, A Questioned Pipeline

That operational strength prompted the company to lift its 2026 guidance on August 4, now expecting adjusted sales and operating profit growth on a constant-currency basis to range from a decline of up to 6 percent to flat — an improvement over the prior range that had anticipated a decline of up to 4 percent.

Yet the second-quarter numbers tell a more complicated story. Reported operating profit fell 16 percent on a CER basis, weighed down by non-cash impairments of DKK 6.3 billion — including DKK 4 billion tied to the pipeline candidate monlunabant. Days earlier, on July 31, the Phase 3 ZEUS trial for Ziltivekimab failed: while the drug hit its IL-6 pathway target, it did not meaningfully reduce major cardiovascular events versus placebo, with a hazard ratio of 0.99. Management insists the outcome leaves the 2026 profit forecast unchanged, though another impairment will hit in the third quarter. Two additional Ziltivekimab studies, HERMES and ARTEMIS, remain ongoing with results expected only in 2027.

The skepticism is sharpest at Goldman Sachs. Analyst James Quigley cut his peak sales estimate for the obesity candidate CagriSema from $11.8 billion to $5 billion on August 4, downgrading the stock to Neutral. Citi followed suit on Friday, trimming its price target from DKK 330 to DKK 310. Two independent houses, two signals pointing in the same direction — that carries more weight than routine target adjustments.

Legal Fronts and Market Positioning

Beyond the clinical and commercial battles, Novo Nordisk is fighting on legal terrain. The company is pursuing Hims & Hers in the US over compounded versions of its weight-loss drugs, while separately sparring with rival Eli Lilly over allegedly misleading dosage comparisons in advertising. The FDA's push to restrict bulk compounding of semaglutide could, if successful, push many cheaper imitators off the market — potentially steering patients back to branded products.

Where the Stock Stands

The shares closed Friday at €40.99, up 2.69 percent on the day, hovering just above the 200-day moving average of €40.30. That technical positioning reflects a market in consolidation mode, with the stock still trading roughly a quarter below its January record high of €54.86.

Germany presents a sterner test than Britain. The country's reimbursement system is more restrictive, and that could slow the pill's adoption curve. Whether the European rollout can replicate the UK's explosive start — and whether the pipeline can deliver credible successes beyond semaglutide — will likely determine if the valuation gap to that January peak narrows. For now, the stock sits in a narrow band, with investors weighing a core business that keeps outperforming against a second-growth story that keeps underdelivering. The upcoming capital markets day should offer some clarity on how seriously the board takes the competitive threat — and how much confidence it truly has in the pill strategy. Until then, patience, not conviction, seems to be the prevailing mood.